Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection

Abstract We aimed to identify predictors of outcomes and survival in patients living in 4 major metropolitan areas who had sickle cell disease (SCD) and COVID-19 to inform best approaches to prevention and care. Data were collected at baseline and during the clinical course in SCD patients diagnosed with COVID-19 in four COVID-19 epicenters. Patients were followed up posthospital discharge for up to 3 months. Of sixty-six SCD patients with COVID-19, fifty patients (75%) required hospitalization, and seven died (10.6%). Patients with preexisting kidney disease (chronic kidney disease) were more likely to be hospitalized. The most common presenting symptom was vaso-occlusive pain. Acute chest syndrome occurred in 30 (60%) of the 50 hospitalized patients and in all who died. Older age and histories of pulmonary hypertension, congestive heart failure, chronic kidney disease, and stroke were more prevalent in patients who died, as were higher creatinine, lactate dehydrogenase, and D-dimer levels. Anticoagulation use while inpatient was twice less common in patients who died. All deaths occurred in individuals not taking hydroxyurea or any other SCD-modifying therapy. Patients with SCD and COVID-19 exhibited a broad range of disease severity. We cannot definitively state that the overall mortality is higher in patients with SCD, although our case fatality rate was ∼10% compared with ∼3% in the general population, despite a median age of 34 years. Individuals with SCD aged >50 years, with preexisting cardiopulmonary, renal disease, and/or stroke not receiving hydroxyurea, who present with high serum creatinine, lactate dehydrogenase, and D-dimer levels, are at higher risk of death, irrespective of genotype or sex.

[1]  Jessica S. Brown,et al.  Characteristics of Persons Who Died with COVID-19 - United States, February 12-May 18, 2020. , 2020, MMWR. Morbidity and mortality weekly report.

[2]  L. Schieve,et al.  Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20–May 21, 2020 , 2020, Emerging infectious diseases.

[3]  E. Flamarion,et al.  Prognosis of patients with sickle cell disease and COVID-19: a French experience , 2020, The Lancet Haematology.

[4]  D. Rees,et al.  COVID-19 in patients with sickle cell disease - a case series from a UK Tertiary Hospital. , 2020, Haematologica.

[5]  K. Khunti,et al.  The impact of ethnicity on clinical outcomes in COVID-19: A systematic review , 2020, EClinicalMedicine.

[6]  S. Renolleau,et al.  Patients with sickle cell disease and suspected COVID‐19 in a paediatric intensive care unit , 2020, British journal of haematology.

[7]  C. Rentsch,et al.  Covid-19 by Race and Ethnicity: A National Cohort Study of 6 Million United States Veterans , 2020, medRxiv.

[8]  L. Kucirka,et al.  Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure , 2020, Annals of Internal Medicine.

[9]  Alberto Borghetti,et al.  Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line , 2020, International Journal of Antimicrobial Agents.

[10]  D. Tsitsikas,et al.  COVID‐19 infection and sickle cell disease: a UK centre experience , 2020, British journal of haematology.

[11]  J. Connors,et al.  COVID-19 and its implications for thrombosis and anticoagulation , 2020, Blood.

[12]  V. Gordeuk,et al.  COVID‐19 infection in patients with sickle cell disease , 2020, British journal of haematology.

[13]  J. Deux,et al.  Rapid and severe Covid‐19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab , 2020, American journal of hematology.

[14]  B. Biemond,et al.  Vaso‐occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID‐19) , 2020, American journal of hematology.

[15]  Xiaowei Yan,et al.  Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 , 2020, The New England journal of medicine.

[16]  Virginia Corbett,et al.  COVID‐19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient , 2020, American journal of hematology.

[17]  T. West,et al.  Covid-19 in Critically Ill Patients in the Seattle Region — Case Series , 2020, The New England journal of medicine.

[18]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[19]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[20]  B. Andrade,et al.  Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients , 2019, Scientific Reports.

[21]  I. Hambleton,et al.  Causes of death and early life determinants of survival in homozygous sickle cell disease: The Jamaican cohort study from birth , 2018, PloS one.

[22]  G. Kato New insights into sickle cell disease: mechanisms and investigational therapies , 2016, Current opinion in hematology.

[23]  I. Tannock,et al.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[24]  C. Haywood,et al.  Mortality Rates and Age at Death from Sickle Cell Disease: U.S., 1979–2005 , 2013, Public health reports.

[25]  C. Scheiermann,et al.  Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. , 2012, Blood.

[26]  S. Weiss,et al.  Coronavirus Pathogenesis , 2011, Advances in Virus Research.

[27]  Mi‐Ok Kim,et al.  The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease , 2011, Pediatric blood & cancer.

[28]  E. Vichinsky,et al.  Novel influenza a (H1N1) viral infection in pediatric patients with sickle‐cell disease , 2011, Pediatric blood & cancer.

[29]  J. Strouse,et al.  Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease. , 2010, Blood.

[30]  B. Biemond,et al.  Acute chest syndrome in sickle cell disease due to the new influenza A (H1N1) virus infection , 2010, American journal of hematology.

[31]  K. Eagle,et al.  Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. , 2008, The American journal of cardiology.

[32]  M. Gladwin,et al.  Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease , 2002, British journal of haematology.